MX2017012068A - Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. - Google Patents

Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.

Info

Publication number
MX2017012068A
MX2017012068A MX2017012068A MX2017012068A MX2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A
Authority
MX
Mexico
Prior art keywords
inhibitory factor
leukemia inhibitory
lif
agents
malignancies
Prior art date
Application number
MX2017012068A
Other languages
English (en)
Inventor
Nickisch Klaus
Santhamma Bindu
Nair Hareesh
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of MX2017012068A publication Critical patent/MX2017012068A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a nuevos compuestos anti-cáncer y métodos para usar tales compuestos, actuando a través de un mecanismo de acción por inhibición simultánea del factor inhibidor de leucemia (LIF) y MDM2. En una modalidad, un compuesto citotóxico tiene la estructura (I) o (II). En una modalidad, un método para tratar el cáncer en un sujeto comprende administrar a un sujeto un medicamento que comprende una cantidad efectiva de un compuesto citotóxico de molécula pequeña que inhibe el factor inhibidor de leucemia o receptor del factor inhibidor de leucemia.
MX2017012068A 2015-03-23 2016-03-22 Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. MX2017012068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562136813P 2015-03-23 2015-03-23
PCT/US2016/023582 WO2016154203A1 (en) 2015-03-23 2016-03-22 Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents

Publications (1)

Publication Number Publication Date
MX2017012068A true MX2017012068A (es) 2018-06-28

Family

ID=56975094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012068A MX2017012068A (es) 2015-03-23 2016-03-22 Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.

Country Status (6)

Country Link
US (2) US10053485B2 (es)
EP (1) EP3273983B1 (es)
AU (1) AU2016235298B2 (es)
CA (1) CA2981173C (es)
MX (1) MX2017012068A (es)
WO (1) WO2016154203A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364743B (es) * 2013-07-11 2019-05-06 Evestra Inc Profármacos de formación de compuestos.
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
AU2016235298B2 (en) * 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
EP3353148A4 (en) * 2015-09-25 2019-04-24 Context Biopharma Inc. PROCESS FOR THE PRODUCTION OF ONAPRISTONE INTERMEDIATE PRODUCTS
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
JP2974760B2 (ja) 1989-01-10 1999-11-10 アムラド・コーポレイション・リミテッド 家畜類種からの白血病阻止因子並びに胎児細胞の移殖及び増殖を促進するためのその用途
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1995010298A1 (en) 1993-10-12 1995-04-20 Mary Lake Polan Method of contraception
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5948822A (en) * 1996-12-17 1999-09-07 Lidak Pharmaceuticals Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
US8784763B2 (en) * 2009-03-13 2014-07-22 Honeywell International Inc. Methods and reactor designs for producing phosphorus pentafluoride
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2011127164A2 (en) * 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
MX364743B (es) * 2013-07-11 2019-05-06 Evestra Inc Profármacos de formación de compuestos.
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
AU2016235298B2 (en) * 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Also Published As

Publication number Publication date
EP3273983A1 (en) 2018-01-31
AU2016235298A1 (en) 2017-10-19
US10738075B2 (en) 2020-08-11
WO2016154203A1 (en) 2016-09-29
US20190153018A1 (en) 2019-05-23
CA2981173C (en) 2024-01-02
CA2981173A1 (en) 2016-09-29
US10053485B2 (en) 2018-08-21
EP3273983B1 (en) 2021-05-05
EP3273983A4 (en) 2018-12-05
AU2016235298B2 (en) 2021-03-11
US20160279145A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MX2017012068A (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
DOP2019000201A (es) Compuestos inhibidores del vih
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12018501669A1 (en) Compositions containing tucaresol or its analogs
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
WO2015154064A3 (en) Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12017501881A1 (en) Methods for treating cancer
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.
PH12021550815A1 (en) New combination solution for treating chemotherapy refractory cancer